Explosionsgefahr bei NEUROMETRIX

Seite 1 von 1
neuester Beitrag: 09.06.17 21:37
eröffnet am: 02.03.11 11:14 von: buran Anzahl Beiträge: 10
neuester Beitrag: 09.06.17 21:37 von: buran Leser gesamt: 2981
davon Heute: 1
bewertet mit 1 Stern

02.03.11 11:14

246009 Postings, 5539 Tage buranExplosionsgefahr bei NEUROMETRIX

deckeln ist angesagt/GrB  

12.05.11 19:36

246009 Postings, 5539 Tage buranLadenburg Thalmann - NeuroMetrix neutral

War der nicht im Zuchthaus der Thämann?Sitzt der noch?  

26.05.11 19:34

246009 Postings, 5539 Tage buranSpecki Konfetti,Umsatz bis jetzt bereits 5.485 $

nicht schlecht was geht an Interessaenten*grinz*  

02.06.11 16:30

246009 Postings, 5539 Tage buranCompany Overview

NeuroMetrix is a science-based company advancing patient care through the development and marketing of innovative medical devices and products that aid physicians in the assessment and treatment of diseases and injuries of peripheral nerves, and that provide regional anesthesia and pain control.

Founded in 1996 and emerging from the Harvard-MIT Division of Health Sciences and Technology, the company?s mission is to:

Create value for our customers by developing innovative neurotechnologies that maximize quality of care
Produce a competitive return on investment for our shareholders
Provide our employees with an opportunity for growth so that they may realize their professional potential
The company is accomplishing these goals by utilizing its core competencies in neurophysiology, biomedical engineering, and information technology.

02.06.11 16:33

246009 Postings, 5539 Tage buranNeuroMetrix

to Exhibit at The Endocrine Society Annual Meeting "ENDO 2011"

Preview for New Product Targeted at Diabetes Market

WALTHAM, Mass., Jun 01, 2011 (BUSINESS WIRE) --

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will exhibit at the annual meeting of The Endocrine Society in Boston on June 4-6, 2011. The exhibition will include a demonstration of its newest product - NC-stat(R)|DPNCheck(TM) which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN).

NC-stat DPNCheck Benefits

May aid in the early detection, confirmation, and monitoring of DPN
Measures sural nerve conduction velocity - a standard biomarker for subclinical and symptomatic DPN
Sensitive and specific for DPN1,2, and predictive of its complications3
Straightforward clinical interpretation
Cost effective

"We are excited to preview NC-stat DPNCheck at ENDO 2011 as it a key milestone in our aggressive timetable to launch this product into the diabetes market," said Shai N. Gozani M.D., PhD., President and Chief Executive Officer of NeuroMetrix. "This point-of-care device should help address the need for a widely available, objective and standardized test for diabetic neuropathy."

NeuroMetrix encourages ENDO 2011 attendees to stop by booth #833-835 to:

Learn more about NC-stat DPNCheck.
View a live demonstration.
Inquire about a no-obligation evaluation.
Meet with NeuroMetrix representatives.

The device is a modified version of the widely used NC-stat(R) device which has been shown to accurately detect DPN1,2. NC-stat DPNCheck will be commercially available in the second half of the year. To learn more, click here.

About NeuroMetrix

NeuroMetrix is a science-based health care company transforming patient care through neurotechnology. We develop and market innovative products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis. For more information, visit http://www.neurometrix.com.


1Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care. September 2006;29(9): 2023-2027.

2Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Multi-Site Testing with a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. Diabetes Care. March 2008;31(3): 522-524.

3Pambianco G, et al. The Assessment of Clinical Distal Symmetric Polyneuropathy in Type 1 Diabetes: A Comparison of Methodologies from the Pittsburgh Epidemiology of Diabetes Complications Cohort. Diabetes Research & Clinical Practice (2011), doi:10.1016/j.diabres.2011.02.005.

SOURCE: NeuroMetrix

NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761CFOneurometrix.ir@neurometrix.com

02.06.11 16:36

246009 Postings, 5539 Tage buranStock Quote

NURO (Common Stock)  
Exchange NASDAQ (US Dollar)
Price $0.45
Change (%)   0.01 (2.17%)
Volume 100
Today's Open $0.00
Previous Close $0.46
Intraday High $0.00
Intraday Low $0.45
52 Week High $1.35
52 Week Low $0.41
Data as of 06/02/11 9:32 a.m. ET
Minimum 20 minute delay - Refresh quote
Angehängte Grafik:

02.06.11 16:38

246009 Postings, 5539 Tage buranStock Chart

Angehängte Grafik:

21.07.11 05:26

246009 Postings, 5539 Tage buran0,50 $

26.12.16 06:59

246009 Postings, 5539 Tage buranExplosionsgefahr bei NEUROMETRIX

kein aktueller Kurs verfügbar ,GrB

09.06.17 21:37

246009 Postings, 5539 Tage buranbestätigen

kein aktueller Kurs verfügbar ,GrB

   Antwort einfügen - nach oben